Metastatic castrate-resistant prostate cancer: dawn of a new age of management

BJU International, 05/10/2012

With current and forthcoming developments in the treatment of metastatic castrate–resistant prostate cancer post–docetaxel, the authors are embarking on an age of potential ‘chronic’ management of this disease. It is hoped that the survival benefits associated with the various treatments, cytotoxic, hormonal and immunotherapeutic, will prove to be additive, providing a multimodal continuum of care. If so, it will be necessary to determine the optimal sequence and timing of the new treatments.

Print Article Summary Cat 2 CME Report